Cel
In IMPACT-AML, a multidisciplinar R/R AML represents a model of high-impact disease, in which no standard of care exists, and where we have an urgent need for new evidence on possible therapies; AML offers the setting in which methodological innovation will combine powerful instruments of clinical trials with personalized medicine through academic efforts. Hereby, we propose to create an inclusive master framework for relapsed or refractory acute myeloid leukemia (STREAM) to include patients with R/R AML across Europe proficiently acquire an unselected population for clinical trials and monitor outcomes including neglected cohorts. Thereafter we will conduct a prospective randomized pragmatic clinical trial (RPCT) that will compare the classical “high intensity” rescue chemotherapy with biology-driven, “low intensity” rescue to obtain “real world” data on the benefit of one of the two different strategies in term of survival also considering patients and caregivers preferences, patient-reported outcomes (PRO), accessibility, affordability, and social cost.
RPCT will aim to evaluate the effectiveness of real-world clinical alternatives in routine care. In addition to retaining the high internal validity of traditional randomized trials, it will maximize external validity, i. e. generalizability of results to many settings. In this context, the inclusion of an RPCT in the master framework will allow a dynamic inclusion and the collection of the excluded population as an instrument to predict the real-life applicability of clinical trial results. We will offer Europe results from an ambitious project, that will go beyond the state of the art in R/R AML demonstrating the superiority of a strategy in a first-of-his-kind clinical trial, providing strong data that will be delivered to national health care providers, policymakers, and health authorities data on optimized and affordable treatment for R/R AML and promoting the implementation of the selected better option. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.
Dziedzina nauki
Słowa kluczowe
Program(-y)
- HORIZON.2.1 - Health Main Programme
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSystem finansowania
HORIZON-RIA - HORIZON Research and Innovation ActionsKoordynator
47014 Meldola
Włochy
Zobacz na mapie
Uczestnicy (16)
08035 Barcelona
Zobacz na mapie
2371 AGIOS DOMETIOS
Zobacz na mapie
00182 Roma
Zobacz na mapie
69469 Weinheim
Zobacz na mapie
46026 Valencia
Zobacz na mapie
00165 Roma
Zobacz na mapie
04289 Leipzig
Zobacz na mapie
625 00 Brno
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
10117 Berlin
Zobacz na mapie
42002 Soria
Zobacz na mapie
1000 Bruxelles / Brussel
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
40126 Bologna
Zobacz na mapie
30625 Hannover
Zobacz na mapie
10115 Berlin
Zobacz na mapie
53100 Siena
Zobacz na mapie
50161 KAUNAS
Zobacz na mapie